Huntington’s Disease—Update on Treatments

Current Neurology and Neuroscience Reports

Volumn 17, Issue 4, 2017, Pages

  Wyant, Kara J ^a   Ridder, Andrew J ^a   Dayalu, Praveen ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Behavioral; Chorea; Cognitive; Huntington; Neurodegeneration; Treatment

Indexed keywords

AMANTADINE; ARIPIPRAZOLE; BENZODIAZEPINE; BOTULINUM TOXIN; CARBAMAZEPINE; CLOMIPRAMINE; CLOZAPINE; DEUTETRABENAZINE; DONEPEZIL; DOPAMINE RECEPTOR STIMULATING AGENT; FLUPHENAZINE; HALOPERIDOL; LAMOTRIGINE; LEVODOPA; MEMANTINE; OLANZAPINE; PERPHENAZINE; PIMOZIDE; PRIDOPIDINE; QUETIAPINE; RILUZOLE; RISPERIDONE; RIVASTIGMINE; SEROTONIN UPTAKE INHIBITOR; TETRABENAZINE; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID; VENLAFAXINE; ZIPRASIDONE;

AGITATION; AGRANULOCYTOSIS; AKATHISIA; ALZHEIMER DISEASE; ANXIETY; APATHY; BRADYKINESIA; BRAIN DEPTH STIMULATION; CHOREA; COGNITIVE BEHAVIORAL THERAPY; COGNITIVE DEFECT; CONFUSION; DELUSION; DEPRESSION; DROWSINESS; DYSTONIA; GENE SILENCING; HALLUCINATION; HUMAN; HUNTINGTON CHOREA; HYPERKINESIA; INSOMNIA; IRRITABILITY; MEDICAL LITERATURE; MENTAL DISEASE; MOTOR DYSFUNCTION; MYOCLONUS; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; OCCUPATIONAL THERAPIST; PERIODIC PARALYSIS; PHYSIOTHERAPY; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEDATION; SEIZURE; SIDE EFFECT; SOMNOLENCE; SUICIDE; ANIMAL; BEHAVIOR; COGNITION DISORDERS; COMPLICATION; HUNTINGTON DISEASE;

ANIMALS; ANXIETY; BEHAVIOR; CHOREA; COGNITION DISORDERS; DEPRESSION; HUMANS; HUNTINGTON DISEASE;

EID: 85015826786     PISSN: 15284042     EISSN: 15346293     Source Type: Journal    
DOI: 10.1007/s11910-017-0739-9     Document Type: Review

References (128)

1. Huntington’s Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell. 1993;72(6):971–83.
2. Deng YP, et al. Differential loss of striatal projection systems in Huntington’s disease: a quantitative immunohistochemical study. J Chem Neuroanat. 2004;27(3):143–64.
3. Reiner A, et al. Differential loss of striatal projection neurons in Huntington disease. Proc Natl Acad Sci. 1988;85(15):5733–7.
4. Hayden MR, et al. Tetrabenazine. Nat Rev Drug Discov. 2009;8(1):17–8.
5. Mehanna R, et al. Analysis of CYP2D6 genotype and response to tetrabenazine. Mov Disord. 2013;28(2):210–5.
6. Kenney C, Hunter C, Jankovic J. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord. 2007;22(2):193–7.
7. Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology. 2006;66(3):366–72.
8. Frank S. Huntington Study Group/TETRA-HD investigators. Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study BMC Neurol. 2009;9:62.
9. Fasano A, et al. The long-term effect of tetrabenazine in the management of Huntington disease. Clin Neuropharmacol. 2008;31(6):313–8.
10. Frank S, et al. A study of chorea after tetrabenazine withdrawal in patients with Huntington disease. Clin Neuropharmacol. 2008;31(3):127–33.
11. Shen V, et al. Safety and efficacy of tetrabenazine and use of concomitant medications during long-term, open-label treatment of chorea associated with Huntington’s and other diseases. Tremor Other Hyperkinet Mov. 2013;3
12. Dorsey ER, et al. Depressed mood and suicidality in individuals exposed to tetrabenazine in a large Huntington disease observational study. J Huntingtons Dis. 2013;2(4):509–15.
13. •• Frank S, et al. Effect of deutetrabenazine on chorea among patients with Huntington disease: a randomized clinical trial. JAMA. 2016;316(1):40–50. A recent trial testing a novel molecule containing deuterium bound to tetrabenazine (TBZ), used to prolong the half-life of TBZ and decrease the side effects. This new medication could potentially allow for better control of chorea with fewer side effects
14. Leonard DP, et al. Letter: double-blind trial of lithium carbonate and haloperidol in Huntington’s chorea. Lancet. 1974;2(7890):1208–9.
15. Shoulson I. Huntington disease: functional capacities in patients treated with neuroleptic and antidepressant drugs. Neurology. 1981;31(10):1333–5.
16. Arena R, et al. Huntington’s disease: clinical effects of a short-term treatment with pimozide. Adv Biochem Psychopharmacol. 1980;24:573–5.
17. Terrence CF. Fluphenazine decanoate in the treatment of chorea: a double-blind study. Curr Ther Res Clin Exp. 1976;20(2):177–83.
18. van Vugt JP, et al. Clozapine versus placebo in Huntington’s disease: a double blind randomised comparative study. J Neurol Neurosurg Psychiatry. 1997;63(1):35–9.
19. Bonuccelli U, et al. Clozapine in Huntington’s chorea. Neurology. 1994;44(5):821–3.
20. Bonelli RM, Mahnert FA, Niederwieser G. Olanzapine for Huntington’s disease: an open label study. Clin Neuropharmacol. 2002;25(5):263–5.
21. Paleacu D, Anca M, Giladi N. Olanzapine in Huntington’s disease. Acta Neurol Scand. 2002;105(6):441–4.
22. Squitieri F, et al. Short-term effects of olanzapine in Huntington disease. Neuropsychiatry Neuropsychol Behav Neurol. 2001;14(1):69–72.
23. Brusa L, et al. Treatment of the symptoms of Huntington’s disease: preliminary results comparing aripiprazole and tetrabenazine. Mov Disord. 2009;24(1):126–9.
24. Cankurtaran ES, et al. Clinical experience with risperidone and memantine in the treatment of Huntington’s disease. J Natl Med Assoc. 2006;98(8):1353–5.
25. Erdemoglu AK, Boratav C. Risperidone in chorea and psychosis of Huntington’s disease. Eur J Neurol. 2002;9(2):182–3.
26. Parsa MA, et al. Risperidone in treatment of choreoathetosis of Huntington’s disease. J Clin Psychopharmacol. 1997;17(2):134–5.
27. Bonelli RM, Niederwieser G. Quetiapine in Huntington’s disease: a first case report. J Neurol. 2002;249(8):1114–5.
28. Bonelli RM, et al. Ziprasidone in Huntington’s disease: the first case reports. J Psychopharmacol. 2003;17(4):459–60.
29. Lundin A, et al. Efficacy and safety of the dopaminergic stabilizer pridopidine (ACR16) in patients with Huntington’s disease. Clin Neuropharmacol. 2010;33(5):260–4.
30. de Yebenes JG, et al. Pridopidine for the treatment of motor function in patients with Huntington’s disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2011;10(12):1049–57.
31. Huntington Study Group. A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington’s disease. Mov Disord. 2013;28(10):1407–15.
32. Lucetti C, et al. IV amantadine improves chorea in Huntington,s disease: an acute randomized, controlled study. Neurology. 2003;60(12):1995–7.
33. Lucetti C, et al. Amantadine in Huntington’s disease: open-label video-blinded study. Neurol Sci. 2002;23(Suppl 2):S83–4.
34. Verhagen ML, et al. Huntington’s disease: a randomized, controlled trial using the NMDA-antagonist amantadine. Neurology. 2002;59(5):694–9.
35. O’Suilleabhain P, Dewey RB. A randomized trial of amantadine in Huntington disease. Arch Neurol. 2003;60(7):996–8.
36. Landwehrmeyer GB, et al. Riluzole in Huntington’s disease: a 3-year, randomized controlled study. Ann Neurol. 2007;62(3):262–72.
37. Huntington Study Group. Dosage effects of riluzole in Huntington’s disease: a multicenter placebo-controlled study. Neurology. 2003;61(11):1551–6.
38. Armstrong MJ, Miyasaki JM. Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology. Neurology. 2012;79(6):597–603.
39. Delorme C, et al. Deep brain stimulation of the internal pallidum in Huntington’s disease patients: clinical outcome and neuronal firing patterns. J Neurol. 2016;263(2):290–8.
40. • Gonzalez V, et al. Deep brain stimulation for Huntington’s disease: long-term results of a prospective open-label study. J Neurosurg. 2014;121(1):114–22. Longitudinal case series of bilateral GPi DBS in patients with pharmacologically resistant chorea secondary to HD. Provides information about long-term outcomes of DBS therapy for chorea in HD
41. Kang GA, et al. Long-term follow-up of pallidal deep brain stimulation in two cases of Huntington’s disease. J Neurol Neurosurg Psychiatry. 2011;82(3):272–7.
42. Moro E, et al. Bilateral globus pallidus stimulation for Huntington’s disease. Ann Neurol. 2004;56(2):290–4.
43. Velez-Lago FM, et al. Differential and better response to deep brain stimulation of chorea compared to dystonia in Huntington’s disease. Stereotact Funct Neurosurg. 2013;91(2):129–33.
44. Lopez-Sendon Moreno JL, et al. A 5-year follow-up of deep brain stimulation in Huntington’s disease. Parkinsonism Relat Disord. 2014;20(2):260–1.
45. Spielberger S, et al. Deep brain stimulation in Huntington’s disease: a 4-year follow-up case report. Mov Disord. 2012;27(6):806–7. author reply 807-8
46. Racette BA, Perlmutter JS. Levodopa responsive parkinsonism in an adult with Huntington’s disease. J Neurol Neurosurg Psychiatry. 1998;65(4):577–9.
47. Reuter I, et al. Late onset levodopa responsive Huntington’s disease with minimal chorea masquerading as Parkinson plus syndrome. J Neurol Neurosurg Psychiatry. 2000;68(2):238–41.
48. Jongen PJ, Renier WO, Gabreels FJ. Seven cases of Huntington’s disease in childhood and levodopa induced improvement in the hypokinetic—rigid form. Clin Neurol Neurosurg. 1980;82(4):251–61.
49. Biolsi B, et al. Long-term follow-up of Huntington disease treated by bilateral deep brain stimulation of the internal globus pallidus. J Neurosurg. 2008;109(1):130–2.
50. Magnet MK, Kapfhammer HP, Bonelli RM. Cabergoline in Huntington’s disease: the first case report. Acta Neurol Scand. 2006;113(5):355–6.
51. Bonelli RM, et al. Pramipexole ameliorates neurologic and psychiatric symptoms in a Westphal variant of Huntington’s disease. Clin Neuropharmacol. 2002;25(1):58–60.
52. Cislaghi G, et al. Bilateral globus pallidus stimulation in Westphal variant of Huntington disease. Neuromodulation. 2014;17(5):502–5.
53. Cubo E, et al. Internal globus pallidotomy in dystonia secondary to Huntington’s disease. Mov Disord. 2000;15(6):1248–51.
54. Saft C, et al. Dose-dependent improvement of myoclonic hyperkinesia due to valproic acid in eight Huntington’s disease patients: a case series. BMC Neurol. 2006;6:11.
55. Thompson PD, et al. Cortical myoclonus in Huntington’s disease. Mov Disord. 1994;9(6):633–41.
56. Vogel CM, et al. Myoclonus in adult Huntington’s disease. Ann Neurol. 1991;29(2):213–5.
57. Paulsen JS, Smith MM, Long JD. Cognitive decline in prodromal Huntington disease: implications for clinical trials. J Neurol Neurosurg Psychiatry. 2013;84(11):1233–9.
58. Paulsen JS, et al. Distinct cognitive profiles of cortical and subcortical dementia in advanced illness. Neurology. 1995;45(5):951–6.
59. Hoth KF, et al. Patients with Huntington’s disease have impaired awareness of cognitive, emotional, and functional abilities. J Clin Exp Neuropsychol. 2007;9(4):365–76.
60. de Tommaso M, et al. Two years’ follow-up of rivastigmine treatment in Huntington disease. Clin Neuropharmacol. 2007;30(1):43–6.
61. Rot U, et al. Rivastigmine in the treatment of Huntington’s disease. Eur J Neurol. 2002;9(6):689–90.
62. Sesok S, et al. Cognitive function in early clinical phase Huntington disease after rivastigmine treatment. Psychiatr Danub. 2014;26(3):239–48.
63. Cubo E, et al. Effect of donepezil on motor and cognitive function in Huntington disease. Neurology. 2006;67(7):1268–71.
64. Ondo WG, Mejia NI, Hunter CB. A pilot study of the clinical efficacy and safety of memantine for Huntington’s disease. Parkinsonism Relat Disord. 2007;13(7):453–4.
65. Beister A, et al. The N-methyl-D-aspartate antagonist memantine retards progression of Huntington’s disease. J Neural Transm Suppl. 2004;68:117–22.
66. Paulsen JS, et al. Neuropsychiatric aspects of Huntington’s disease. J Neurol Neurosurg Psychiatry. 2001;71(3):310–4.
67. Levy ML, et al. Apathy is not depression. J Neuropsychiatry Clin Neurosci. 1998;10(3):314–9.
68. Duff K, et al. Psychiatric symptoms in Huntington’s disease before diagnosis: the predict-HD study. Biol Psychiatry. 2007;62(12):1341–6.
69. Nehl C, Paulsen JS. Cognitive and psychiatric aspects of Huntington disease contribute to functional capacity. J Nerv Ment Dis. 2004;192(1):72–4.
70. van Duijn E, et al. Neuropsychiatric symptoms in a European Huntington’s disease cohort (REGISTRY). J Neurol Neurosurg Psychiatry. 2014;85(12):1411–8.
71. van Duijn E, Kingma EM, van der Mast RC. Psychopathology in verified Huntington’s disease gene carriers. J Neuropsychiatry Clin Neurosci. 2007;19(4):441–8.
72. Moulton CD, Hopkins CW, Bevan-Jones WR. Systematic review of pharmacological treatments for depressive symptoms in Huntington’s disease. Mov Disord. 2014;29(12):1556–61.
73. Como PG, et al. A controlled trial of fluoxetine in nondepressed patients with Huntington’s disease. Mov Disord. 1997;12(3):397–401.
74. Beglinger LJ, et al. Results of the citalopram to enhance cognition in Huntington disease trial. Mov Disord. 2014;29(3):401–5.
75. Holl AK, et al. Combating depression in Huntington’s disease: effective antidepressive treatment with venlafaxine XR. Int Clin Psychopharmacol. 2010;25(1):46–50.
76. Duff K, et al. Risperidone and the treatment of psychiatric, motor, and cognitive symptoms in Huntington’s disease. Ann Clin Psychiatry. 2008;20(1):1–3.
77. Ciammola A, et al. Aripiprazole in the treatment of Huntington’s disease: a case series. Neuropsychiatr Dis Treat. 2009;5:1–4.
78. Sajatovic M, et al. Clozapine treatment of psychiatric symptoms resistant to neuroleptic treatment in patients with Huntington’s chorea. Neurology. 1991;41(1):156.
79. Johnston TG. Risperidone long-acting injection and Huntington’s disease: case series with significant psychiatric and behavioural symptoms. Int Clin Psychopharmacol. 2011;26(2):114–9.
80. Lewis CF, DeQuardo JR, Tandon R. ECT in genetically confirmed Huntington’s disease. J Neuropsychiatry Clin Neurosci. 1996;8(2):209–10.
81. Ranen NG, Peyser CE, Folstein SE. ECT as a treatment for depression in Huntington’s disease. J Neuropsychiatry Clin Neurosci. 1994;6(2):154–9.
82. Cusin C, et al. Rapid improvement of depression and psychotic symptoms in Huntington’s disease: a retrospective chart review of seven patients treated with electroconvulsive therapy. Gen Hosp Psychiatry. 2013;35(6):678. e3-5
83. Paulsen JS, et al. Depression and stages of Huntington’s disease. J Neuropsychiatry Clin Neurosci. 2005;17(4):496–502.
84. Di Maio L, et al. Suicide risk in Huntington’s disease. J Med Genet. 1993;30(4):293–5.
85. Lipe H, Schultz A, Bird TD. Risk factors for suicide in Huntingtons disease: a retrospective case controlled study. Am J Med Genet. 1993;48(4):231–3.
86. Wetzel HH, et al. Suicidal ideation in Huntington disease: the role of comorbidity. Psychiatry Res. 2011;188(3):372–6.
87. Krishnamoorthy A, Craufurd D. Treatment of apathy in Huntington’s disease and other movement disorders. Curr Treat Options Neurol. 2011;13(5):508–19.
88. De Marchi N, Daniele F, Ragone MA. Fluoxetine in the treatment of Huntington’s disease. Psychopharmacology. 2001;153(2):264–6.
89. Patzold T, Brune M. Obsessive compulsive disorder in Huntington disease: a case of isolated obsessions successfully treated with sertraline. Neuropsychiatry Neuropsychol Behav Neurol. 2002;15(3):216–9.
90. Anderson K, et al. An international survey-based algorithm for the pharmacologic treatment of obsessive-compulsive behaviors in Huntington’s disease. PLoS Curr. 2011;3:Rrn1261.
91. Ranen NG, et al. Sertraline in the treatment of severe aggressiveness in Huntington’s disease. J Neuropsychiatry Clin Neurosci. 1996;8(3):338–40.
92. Groves M, et al. An international survey-based algorithm for the pharmacologic treatment of irritability in Huntington’s disease. PLoS Curr. 2011;3:Rrn1259.
93. Madhusoodanan S, Brenner R. Use of risperidone in psychosis associated with Huntington’s disease. Am J Geriatr Psychiatry. 1998;6(4):347–9.
94. Seitz DP, Millson RC. Quetiapine in the management of psychosis secondary to Huntington’s disease: a case report. Can J Psychiatr. 2004;49(6):413.
95. Alpay M, Koroshetz WJ. Quetiapine in the treatment of behavioral disturbances in patients with Huntington’s disease. Psychosomatics. 2006;47(1):70–2.
96. Correia K, et al. The genetic modifiers of motor onsetAge (GeM MOA) website: genome-wide association analysis for genetic modifiers of Huntington’s disease. J Huntingtons Dis. 2015;4(3):279–84.
97. Genetic Modifiers of Huntington’s Disease Consortium. Identification of genetic factors that modify clinical onset of Huntington’s disease. Cell. 2015;162(3):516–26.
98. Godinho BM, et al. Delivering a disease-modifying treatment for Huntington’s disease. Drug Discov Today. 2015;20(1):50–64.
99. Shannon KM, Fraint A. Therapeutic advances in Huntington’s disease. Mov Disord. 2015;30(11):1539–46.
100. Dayalu P, Albin RL. Huntington disease: pathogenesis and treatment. Neurol Clin. 2015;33(1):101–14.
101. Huntington Study Group. Announcement of CREST-E early study closure. 2014: HuntingtonStudyGroup.org.
102. Huntington Study Group. Announcement of 2CARE early study closure. 2012: HuntingtonStudyGroup.org.
103. Huntington Study Group Reach. H.D.I. Safety, tolerability, and efficacy of PBT2 in Huntington’s disease: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2015;14(1):39–47.
104. Sussmuth SD, et al. An exploratory double-blind, randomized clinical trial with selisistat, a SirT1 inhibitor, in patients with Huntington’s disease. Br J Clin Pharmacol. 2015;79(3):465–76.
105. Achey M.A.B. Meet the compound: RP103 (cysteamine bitartrate delayed-release). 2015 [cited 2016; Available from: http://huntingtonstudygroup.org/hd-insights/meet-the-compound-rp103-cysteamine-bitartrate-delayed-release/.]
106. Multicentric Trial of the Treatment of Huntington’s Disease by Cysteamine (RP103). 2013 [cited 2016; Available from: https://clinicaltrials.gov/ct2/show/NCT02101957.]
107. Corey-Bloom J, et al. Disease modifying potential of glatiramer acetate in Huntington’s disease. J Huntingtons Dis. 2014;3(3):311–6.
108. Pasinetti GM, et al. Neuroprotective and metabolic effects of resveratrol: therapeutic implications for Huntington’s disease and other neurodegenerative disorders. Exp Neurol. 2011;232(1):1–6.
109. Naia L, Rego AC. Sirtuins: double players in Huntington’s disease. Biochim Biophys Acta. 2015;1852(10 Pt A):2183–94.
110. Kremer B, et al. Influence of lamotrigine on progression of early Huntington disease: a randomized clinical trial. Neurology. 1999;53(5):1000–11.
111. Huntington Study Group DOMINO Investigators. A futility study of minocycline in Huntington’s disease. Mov Disord. 2010;25(13):2219–24.
112. Chan JH, Lim S, Wong WS. Antisense oligonucleotides: from design to therapeutic application. Clin Exp Pharmacol Physiol. 2006;33(5–6):533–40.
113. Kay C, et al. Personalized gene silencing therapeutics for Huntington disease. Clin Genet. 2014;86(1):29–36.
114. • Skotte NH, et al. Allele-specific suppression of mutant huntingtin using antisense oligonucleotides: providing a therapeutic option for all Huntington disease patients. PLoS One. 2014;9(9):e107434. Article describing development of stable ASOs targeting SNPs found on a majority of mutant alleles to stop production of mhtt
115. Gagnon KT, et al. Allele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat. Biochemistry. 2010;49(47):10166–78.
116. Hu J, Matsui M, Corey DR. Allele-selective inhibition of mutant huntingtin by peptide nucleic acid-peptide conjugates, locked nucleic acid, and small interfering RNA. Ann N Y Acad Sci. 2009;1175:24–31.
117. Sun X, et al. Phosphorodiamidate morpholino oligomers suppress mutant huntingtin expression and attenuate neurotoxicity. Hum Mol Genet. 2014;23(23):6302–17.
118. Kordasiewicz HB, et al. Sustained therapeutic reversal of Huntington’s disease by transient repression of huntingtin synthesis. Neuron. 2012;74(6):1031–44.
119. Carroll JB, et al. Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene/allele-specific silencing of mutant huntingtin. Mol Ther. 2011;19(12):2178–85.
120. Wild EJ, Tabrizi SJ. Targets for future clinical trials in Huntington’s disease: what’s in the pipeline? Mov Disord. 2014;29(11):1434–45.
121. Miller TM, et al. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol. 2013;12(5):435–42.
122. Ionis Pharmaceuticals, Inc. Safety, tolerability, pharmacokinetics, and pharmacodynamics of IONIS-HTTRx in patients with early manifest Huntington's disease. Bethesda: National Library of Medicine (US); 2000. https://clinicaltrials.gov/ct2/show/NCT02519036.
123. • Aronin N, DiFiglia M. Huntingtin-lowering strategies in Huntington’s disease: antisense oligonucleotides, small RNAs, and gene editing. Mov Disord. 2014;29(11):1455–61. Review article describing in greater detail the function and limitations of various genetic approaches at gene silencing for HD
124. Kumar A, et al. Huntington’s disease: an update of therapeutic strategies. Gene. 2015;556(2):91–7.
125. Stanek LM, et al. Silencing mutant huntingtin by adeno-associated virus-mediated RNA interference ameliorates disease manifestations in the YAC128 mouse model of Huntington’s disease. Hum Gene Ther. 2014;25(5):461–74.
126. Rolle K, et al. Promising human brain tumors therapy with interference RNA intervention (iRNAi). Cancer Biol Ther. 2010;9(5):396–406.
127. Moreno-Montanes J, et al. Phase I clinical trial of SYL040012, a small interfering RNA targeting beta-adrenergic receptor 2, for lowering intraocular pressure. Mol Ther. 2014;22(1):226–32.
128. Garriga-Canut M, et al. Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6/2 mice. Proc Natl Acad Sci. 2012;109(45):E3136–45.